Glenmark Pharmaceuticals Gets Indian Approval for Favipiravir as a COVID-19 Treatment

Glenmark Pharmaceuticals has earned approval in India for emergency use of its influenza antiviral favipiravir for the treatment of mild-to-moderate COVID-19.

The Mumbai-based drugmaker plans to market the antiviral as FabiFlu. The drug was only approved for restricted emergency use.

Glenmark is also conducting phase 3 trials of favipiravir as a COVID-19 monotherapy in nine hospitals across India.